Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navuzumab
- Development stage
- Unknown
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Navuzumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor. Developed by the Cancer Center of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, it is designed to block the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, on tumor cells. This blockade prevents the inhibitory signaling that tumors use to evade the immune system, thereby restoring and enhancing the anti-tumor activity of T cells. Navuzumab is primarily being evaluated in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumors, either as a monotherapy or in combination with other agents.
- Other names
- navuzumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on navuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navuzumab.